A5044634922- Liver Disease Diagnosis and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Hepatitis B Virus Studies
- Hepatitis C virus research
- Liver Disease and Transplantation
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer, Lipids, and Metabolism
- Organ Transplantation Techniques and Outcomes
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Immune Cell Function and Interaction
- Alcohol Consumption and Health Effects
- Liver Diseases and Immunity
- Colorectal Cancer Treatments and Studies
- Folate and B Vitamins Research
- HIV/AIDS drug development and treatment
- Liver physiology and pathology
- Genetic and Kidney Cyst Diseases
- Viral-associated cancers and disorders
- Cancer, Hypoxia, and Metabolism
- Pancreatitis Pathology and Treatment
- Pediatric Hepatobiliary Diseases and Treatments
- Hepatitis Viruses Studies and Epidemiology
- Diet, Metabolism, and Disease
Samsung Medical Center
2016-2025
Sungkyunkwan University
2016-2025
Hallym University Dongtan Sacred Heart Hospital
2024
Samsung (South Korea)
2018
Asan Medical Center
2017
Creative Commons
2016
Johns Hopkins University
2016
October 6 University
2016
Jacobson Holman (United States)
2016
Inje University
2013
The current recommendation of ribavirin dose for the treatment chronic hepatitis C is based on study results Western patients, and might not be optimal Korean patients because different body frames.A total 163 treatment-naive genotype 1 who received combination therapy with pegylated interferon a-2a were reviewed.Under dosing, only 49% started 13-15mg/kg (targeted dose), while 45% 6% =16mg/kg <13mg/kg, respectively. Patients higher experienced more modification during (55%, 31% 11% =16mg/kg,...
No adjuvant therapy has been shown to extend the survival of patients with hepatocellular carcinoma (HCC) receiving curative treatment. We investigated whether injections activated cytokine-induced killer (CIK) cells (CD3+/CD56+ and CD3+/CD56- T CD3-/CD56+ natural cells) prolongs recurrence-free after for HCC.We performed a multicenter, randomized, open-label, phase 3 trial efficacy safety immunotherapy CIK (created by incubation patients' peripheral blood mononuclear interleukin 2 an...
The long‐term clinical impact of low‐level viremia (LLV; <2,000 IU/mL) is not well understood. As a result, it unclear whether the development LLV during entecavir monotherapy requires change in therapy. A retrospective cohort 875 treatment‐naive chronic hepatitis B virus (HBV) monoinfected patients (mean age 47.7 years, male = 564 [65.5%], cirrhosis 443 [50.6%]) who received were analyzed for hepatocellular carcinoma (HCC). HCC risk was compared between maintained virological response...
Abstract Background A limited number of studies have characterized genomic properties hepatocellular carcinoma (HCC) patients in response to anti-PD-1 immunotherapy. Methods Herein, we performed comprehensive molecular characterization immediate (D-42 D-1) pre-treatment tumor biopsy specimens from 60 with sorafenib-failed HCC a single-arm prospective phase II trial pembrolizumab. Objective rate was the primary efficacy endpoint. We used whole-exome sequencing, RNA and correlative analysis....
To compare the efficacy of radiofrequency ablation (RFA) and surgical resection in a group patients with Child-Pugh score 5 single HCC less than 4 cm diameter.Radiofrequency has become popular method for treatment hepatocellular carcinoma (HCC) been applied as an alternative primary therapy to resection.We compared outcomes 148 treated RFA (n = 55) those surgically 93).The rate local recurrence among was significantly higher surgery (P 0.005), while incidence remote similar between two...
<h3>Background</h3> It is generally stated that oral antiviral therapy in patients with chronic hepatitis B (CHB) decreases the risk of developing hepatocellular carcinoma (HCC). Although nucleos(t)ide analogues (NUCs) may induce a state similar to inactive stage CHB, long-term for HCC treated NUCs compared CHB unclear. <h3>Methods</h3> A total 1378 who were treatment naïve and started NUC 1014 HBeAg-negative continuously had DNA <2000 IU/mL during follow-up enrolled. The group was...
Controversy exists about whether antiviral therapy (AVT) should be recommended for compensated cirrhosis patients with chronic hepatitis B virus (HBV) infection and detectable, but low, serum HBV‐DNA levels. A retrospective cohort of 385 treatment‐naïve, HBV‐related (mean age: 51.1 ± 9.7 years; 66% male) low levels (<2,000 IU/mL) was assessed the development hepatocellular carcinoma (HCC). During a median 5.6 years follow‐up, HCC had developed in 37 (9.6%) patients. The 5‐year cumulative...
OBJECTIVES: We assessed the association among ultrasonographically detected non-alcoholic fatty liver disease (US-NAFLD), metabolic syndrome (MetS), and insulin resistance (IR) in non-obese, non-diabetic middle-aged adults, to find out whether US-NAFLD is independently associated with IR this population. METHODS: A total of 5,878 non-obese (body mass index, ≥18.5 <25), individuals were analyzed. was estimated homeostasis model assessment index (HOMA2–IR) defined when HOMA2–IR ≥1.5. MetS by...
Background and Aims Statins have pleiotropic effects that may include chemoprevention. Several observational studies suggested statins prevent hepatocellular carcinoma (HCC), but they not yet been fully studied in patients with chronic hepatitis B virus (HBV) infections. Approach Results A hospital‐based retrospective cohort of 7,713 HBV‐infected individuals between January 2008 December 2012 were analyzed. The primary outcome was the development HCC. Patients who used for at least 28...
Given the complexity of managing hepatocellular carcinoma (HCC), a multidisciplinary approach (MDT) is recommended to optimize management HCC patients. However, evidence suggesting that MDT improves patient outcome limited.We performed retrospective cohort study all patients newly-diagnosed with between 2005 and 2013 (n = 6,619). The overall survival (OS) rates who were not managed via compared in entire 6,619), exactly matched 1,396).In cohort, 5-year rate was significantly higher (71.2%...
Sorafenib is an orally active multikinase inhibitor approved for the treatment of advanced hepatocellular carcinoma (HCC). However, clinical parameters that may predict outcomes in sorafenib-treated HCC patients remains unknown.A total 99 (BCLC C) treated with sorafenib as initial modality from January 2007 to December 2011 were retrospectively reviewed. Overall survival was primary endpoint analysis. Various including tumour stage and adverse effects analysed. Univariate multivariate...
Our earlier multicenter randomized controlled trial showed that adjuvant immunotherapy with cytokine-induced killer (CIK) cells resulted in longer recurrence-free survival (RFS) and overall (OS) as well patients who received curative treatment for hepatocellular carcinoma (HCC). In the present study, we determined if efficacy of CIK cell therapy continued after end repeated injections. We performed a follow-up study our preceding trial. included 226 patients: 114 group (injection 6.4 × 109...
The Baveno VI and the expanded criteria were proposed to help identify patients who could safely avoid screening endoscopies for clinically significant varices among with compensated advanced chronic liver disease. However, these require cross-validation, especially in Asian populations where aetiologies of disease are different.A total 1035 patients, including 282 different aetiology, analysed. was defined by stiffness measurement ≥10 kPa, Child-Pugh class A absence prior decompensation....
Background/Aims: Although hepatocellular carcinoma (HCC) is notorious for its high recurrence rate, some patients do not experience more than 5 years after resection or radiofrequency ablation early-stage HCC. For those with five recurrence-free period, the risk of HCC within next remains unknown.Methods: A total 1,451 consecutive (median, 55 old; males, 79.0%; hepatitis B virus-related, 79.3%) good liver function (Child-Pugh class A) diagnosed by Barcelona Clinic Liver Cancer Staging and...
The metabolic dysfunction-associated fatty liver disease (MAFLD) is a new inclusive term proposed to replace non-alcoholic (NAFLD). We analysed whether hepatocellular carcinoma (HCC) risk differs by MAFLD or NAFLD status in large sample of asymptomatic adults.A cohort comprising 73,691 adults were followed up for the development HCC. was diagnosed among participants without other diseases (n = 65,992).Participants with showed higher incidence HCC than those (0.37 and 0.24 per 1,000...
<b><i>Introduction:</i></b> Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed cancer and third leading cause of death worldwide. While there has been rapid evolution in treatment paradigm HCC across past decade, extent to which these newly approved therapies are utilized clinical practice real world is, however, unknown. The INSIGHT study was an investigator-initiated, multi-site longitudinal cohort conducted reflect real-world epidemiology...
Abstract Background Hepatectomy is the standard treatment for HCC. However, large HCC poses a difficult challenge because of technical complexity surgical resection and fear postoperative hepatic decompensation. We analyzed outcome prognostic factors in patients with hepatocellular carcinoma (HCC ≥10 cm) after surgery. Methods retrospectively investigated medical records 91 who had undergone hepatectomy between January 2006 June 2010. A survival analysis was performed utilizing Kaplan-Meier...
Abstract Background & Aims Sorafenib is regarded as the standard treatment of care in Barcelona Clinic Liver Cancer ( BCLC ) stage C patients. However, modest overall survival OS and disease control rate warrants for a better modality. This study aimed to investigate feasibility combined transarterial chemoembolization radiotherapy TACE + RT comparison with sorafenib advanced hepatocellular carcinoma HCC ). Methods Materials From 2007 2011, total 116 patients locally were retrospectively...
Several staging systems have been proposed for hepatocellular carcinoma (HCC). Among them, only the Barcelona Clinic Liver Cancer (BCLC) and Hong Kong (HKLC) also recommend treatment modality. This study was designed to see whether BCLC HKLC can guide strategy, so analyzed patients survival is better those who received recommended therapy by each system.A total of 3515 treatment-naïve, newly diagnosed HCC at a single centre were analyzed.Five-year rates according stages: 0 = 79.1%, A 62.9%,...
Portal vein invasion (PVI) and extrahepatic spread (ES) are two tumor-related factors that define advanced stage in the Barcelona Clinic Liver Cancer (BCLC) staging system (BCLC C), recommended first line therapy this is sorafenib. However, extent of PVI type ES may affect patient prognosis as well treatment outcome. This study analyzed survival BCLC C HCC patients order to see whether sub-classification necessary. A total 582 naïve, [age: 54.3 ± 10.8 years, males = 494 (84.9%), hepatitis B...